Cue-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies
Steven N. Quayle, Natasha Girgis, Dharma R. Thapa, Zohra Merazga, Melissa M. Kemp, Alex Histed, Fan Zhao, Miguel Moreta, Paige Ruthardt, Sandrine Hulot, Alyssa Nelson, Lauren D. Kraemer, Dominic R. Beal, Luke Witt, Jessica Ryabin, Jonathan Soriano, Mark Haydock, Emily Spaulding, John F. Ross, Peter A. KienerSteven Almo, Rodolfo Chaparro, Ronald D. Seidel, Anish Suri, Saso Cemerski, Kenneth J. Pienta, Mary Ellen Simcox
Dive into the research topics of 'Cue-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies'. Together they form a unique fingerprint.